- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02403180
DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance
July 10, 2016 updated by: Alcon Research
Comparative Assessment of Visual Performance Between DAILIES® AquaComfort Plus® (DACP) Multifocal (MF) and PROCLEAR 1 Day Multifocal (PROCLEAR 1D MF)
The purpose of this study is to evaluate the visual performance of DACP MF and PROCLEAR 1D MF daily disposable contact lenses in an established presbyopic population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
41 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must sign an informed consent;
- Adapted soft contact lens wearer;
- Vision correctable to 20/30 [(0.2 logMAR (logarithm of the minimum angle of resolution)] or better in each eye at distance;
- Willing to wear lenses every day or for at least 5 days per week, 6 hours per day;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Currently wearing multifocal contact lenses;
- Currently wearing monovision;
- Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear;
- Use of systemic or ocular medications which could contraindicate contact lens wear;
- Eye injury or surgery within 12 weeks prior to enrollment;
- Prior refractive surgery;
- Monocular (only 1 eye with functional vision) or fit with only 1 lens;
- Other protocol-specified exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: DACP MF, then PROCLEAR 1D MF
DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
|
Nelfilcon A multifocal contact lenses
Other Names:
Omafilcon A multifocal contact lenses
Other Names:
|
Other: PROCLEAR 1D MF, then DACP MF
PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
|
Nelfilcon A multifocal contact lenses
Other Names:
Omafilcon A multifocal contact lenses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Stereoacuity at Near After 5+/-1 Days of Contact Lens Wear
Time Frame: Day 5, each product
|
Stereoacuity (SA) is the ability to detect differences in distance (depth perception).
Near SA was measured at a distance of 40 cm using the Howard-Dolman system.
A lower SA value indicates better depth perception.
|
Day 5, each product
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Area of Focus Under the Mean Defocus Curve After 5 +/- 1 Days of Contact Lens Wear
Time Frame: Day 5, each product
|
Visual acuity was measured with contact lenses in place using an Early Treatment Diabetic Retinopathy Study (ETDRS) high contrast logMAR chart under well-lit conditions.
Trial Lenses of different spherical powers (+2.00 diopter to -5.00 diopter) were placed in front of the eyes to produce varying levels of defocus, and logMAR acuity at each defocus value was recorded.
The area under the defocus curve (AUC) was calculated via the trapezoidal rule for the entire study population by treatment using a 0.3 logMAR threshold for intermediate from -2.00 D (50cm) to -0.50 D (2m) and near from -4.00 D (25cm) to -2.00 D (50cm).
A higher value indicates a bigger area of focus.
|
Day 5, each product
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Manager, Alcon, Spain
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
July 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
March 26, 2015
First Submitted That Met QC Criteria
March 26, 2015
First Posted (Estimate)
March 31, 2015
Study Record Updates
Last Update Posted (Estimate)
August 18, 2016
Last Update Submitted That Met QC Criteria
July 10, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLW681-P001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
Lee, Steven, M.D.CompletedMyopia, | Hyperopia, | Astigmatism, | Presbyopia, | Eye Strain,
-
Allotex, Inc.RecruitingPresbyopiaCzechia, Ireland, Turkey, United Kingdom
-
Coopervision, Inc.Centre for Ocular Research & Education, CanadaRecruitingPresbyopiaUnited States, Canada
-
Optall VisionRecruiting
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.LENZ Therapeutics, IncCompleted
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Coopervision, Inc.CORECompletedPresbyopiaUnited States, Canada
Clinical Trials on DACP MF
-
Alcon ResearchCompletedRefractive Error | Presbyopia
-
Alcon ResearchCompleted
-
Alcon ResearchTerminated
-
Bausch & Lomb IncorporatedCompleted
-
Purdue UniversityUniversity of OregonNot yet recruiting
-
Purdue UniversityNot yet recruiting
-
Alcon ResearchCompleted
-
Coopervision, Inc.Completed
-
Campus Bio-Medico UniversityUniversity of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... and other collaboratorsTerminatedIschemic Stroke | Stroke, AcuteItaly
-
VA Office of Research and DevelopmentNot yet recruitingDepression | Anxiety | Post Traumatic Stress Disorder (PTSD)United States